We anticipate a profitable buying opportunity for investors in Merck stock following a 15% decline in July. See why we ...

Intermediate-stage hepatocellular carcinoma remains a challenge to treat. The new findings may lead to a new treatment ...

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

He began his career in the pharmaceutical industry in 1996 when he joined Merck, Sharp & Dohme (MSD) at the UK subsidiary, advancing through different roles in the business around the world.

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of ...

After Summit Therapeutics (NASDAQ:SMMT) said early this week that its lead asset ivonescimab outperformed Merck's (NYSE:MRK) ...

Sun Pharma has acquired the rights from Merck, Sharp & Dohme (MSD) to develop, manufacture, and commercialise Tedizolid Phosphate in India. ABSSSIs, are more challenging to treat due to the ...

Comparing the Diagnostic Yield of Germline Exome Versus Panel Sequencing in the Diverse Population of the Texas KidsCanSeq Pediatric Cancer Study This mixed-methods, prospective cross-institutional ...

Merck Sharp & Dohme LLC has identified plasma kallikrein (KLKB1) Inhibitors reported to be useful for the treatment of diabetic retinopathy, retinal vein occlusion, hereditary angioedema, diabetes, ...